Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;7(5):787-94.
doi: 10.1111/j.1538-7836.2009.03332.x. Epub 2009 Mar 5.

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort

P W Collins  1 , M Mathias, J Hanley, D Keeling, R Keenan, M Laffan, D Perry, R Liesner; UK Haemophilia Centre Doctors' Organisation
Affiliations
Free article

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort

P W Collins et al. J Thromb Haemost. 2009 May.
Free article

Abstract

SUMMARY BACKGROUND AND OBJECTIVES: he management of patients with severe hemophilia A and inhibitors to factor VIII (FVIII) resistant to standard immune tolerance is challenging. There have been recent case reports of the successful use of rituximab in up to 57% of patients as part of rescue immune tolerance regimens. Because case reports and small series are prone to the potential bias of reporting good outcomes and relatively short follow up, a consecutive cohort of all patients treated in the UK with prolonged follow up was analyzed.

Methods: A national survey of all Comprehensive Care Haemophilia Center in the UK.

Results: A total of 15 patients were reported of whom six (40%) achieved a negative inhibitor titer by Bethesda assay. Durable responses were unusual, observed in only 14% of cases. Clinically significant responses with either a negative inhibitor or an inhibitor titer < 5 BU mL(-1) and no spontaneous bleeding with FVIII replacement were observed in seven (47%) cases. Concomitant use of FVIII appeared to be important. Of the 12 patients treated with rituximab and FVIII, six (50%) achieved a negative inhibitor titer and seven (58%) had a clinically beneficial response. None of the three patients treated without FVIII responded.

Conclusions: These data suggest that the use of rituximab combined with FVIII is a potentially useful treatment for patients with inhibitors resistant to standard immune tolerance, although sustained inhibitor eradication is uncommon.

PubMed Disclaimer

Comment in

Substances